Compounding pharmacists assign a beyond-use date every time they complete a nonsterile or sterile preparation, and the date carries more legal weight than many pharmacists assume. A BUD works differently than a manufacturer's expiration date, functioning as a conservative estimate of how long a specific compounded preparation remains suitable for use once made, based on the ingredients, the compounding environment, and whatever stability or sterility data actually supports that exact formulation. USP 797/800 and USP General Chapter <795> set the default limits a pharmacy must use absent that data, and both FDA and state boards of pharmacy treat beyond-use dating as one of the most heavily scrutinized parts of a compounding inspection.
Beyond-Use Dates Differ From Manufacturer Expiration Dates
A manufactured drug's expiration date rests on stability testing the manufacturer submits to FDA as part of an approved application, testing that covers the exact commercial formulation, packaging, and storage conditions. A compounded preparation has no equivalent pre-market review behind it. The compounding pharmacy is responsible for either generating its own stability-indicating testing on the specific formulation and container-closure system, or defaulting to the conservative time limits USP sets for pharmacies that have not generated that data. Defaulting to the conservative limit carries no penalty on its own. Assigning a longer beyond-use date without the testing to support it does.
Default BUD Limits Under USP <795> and <797>
The current versions of USP General Chapter <795> and USP 797/800 became official on November 1, 2023, following an appeals process that delayed the standards USP originally published in 2019. Under the current default beyond-use date limits, nonsterile preparations compounded under <795> carry default dates of 14 days for non-preserved aqueous preparations, 35 days for preserved aqueous preparations, 90 days for nonaqueous dosage forms, and 180 days for solid dosage forms. Sterile preparations compounded under <797> fall into Category 1, prepared in an unclassified segregated compounding area with a default limit of 12 hours at controlled room temperature or 24 hours refrigerated, and Category 2, prepared in a cleanroom suite, where the default ranges from 1 day at room temperature and 4 days refrigerated for preparations made with any nonsterile starting component, up to 4 days at room temperature and 10 days refrigerated for preparations made entirely from sterile starting components without sterility testing. Extending any of these figures requires validated stability-indicating testing performed on the actual formulation and container, plus sterility and endotoxin testing for sterile preparations. The category structure applies whether the pharmacy compounds under a 503A or 503B framework. For how that distinction affects other compliance obligations, see 503A vs 503B: Which Framework Governs Your Compounding.
The default beyond-use date is a ceiling a pharmacy may use only until it generates the data to justify something longer.
Common Citation Patterns in Inspections
FDA's oversight of compounding pharmacies and state board of pharmacy inspection programs return to the same handful of fact patterns when they cite beyond-use dating errors. A pharmacy assigns a beyond-use date that exceeds the applicable USP default without a written, formulation-specific stability study behind it. A stability study performed on a different concentration or container-closure system gets applied to a preparation it does not actually cover. In other cases, the pharmacy has no documented stability or sterility testing program at all, so every beyond-use date on the shelf is effectively unsupported regardless of what is printed on the label. Any of these findings can appear as an FDA Form 483 observation or a state board inspection deficiency, and either can escalate from a corrective action plan to a consent order, license restriction, or product recall if patients received preparations dated beyond what the pharmacy could actually support.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain healthcare defense counsel upon receiving an FDA Form 483, a state board of pharmacy inspection finding, or another government inquiry citing beyond-use dating errors. Early legal intervention can protect the pharmacy's rights, help ensure appropriate responses to inspectors' requests, avoid inadvertent admissions about stability practices still being corrected, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary licensure, financial, and reputational risk.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies and pharmacists facing FDA inspections, state board of pharmacy investigations, and enforcement matters built on beyond-use dating findings. We review the underlying stability and sterility documentation, assess whether the cited beyond-use dates actually exceeded the applicable USP default, and communicate with inspectors and investigators on the pharmacy's behalf while a matter is still at the inspection or informal-inquiry stage. If your pharmacy has received an FDA Form 483, a state board notice, or another inquiry tied to beyond-use dating practices, contact us for a free, confidential consultation.
